Gut‒heart axis: emerging therapies targeting trimethylamine N-oxide production
Efrain Ricardo Torres1, Jennifer Wilcox2, W H Wilson Tang2,3,4
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Gut Microbes
|December 27, 2025
Summary
Trimethylamine N-oxide (TMAO) is linked to heart and kidney disease. TMA lyase inhibitors effectively lower TMAO levels, improving cardiovascular health and renal function.
Area of Science:
- Biochemistry
- Microbiology
- Cardiovascular Medicine
Background:
- Trimethylamine N-oxide (TMAO) is implicated in heart and kidney disease pathogenesis.
- Gut microbes convert dietary precursors into trimethylamine (TMA), which the liver metabolizes into TMAO.
- Elevated TMAO levels contribute to dyslipidemia, metabolic syndrome, endothelial dysfunction, and inflammation.
Purpose of the Study:
- To investigate the role of TMA lyase inhibitors in managing TMAO-related disorders.
- To evaluate the clinical outcomes associated with TMAO reduction therapies.
Main Methods:
- Review of studies on existing medications affecting TMAO levels.
- Analysis of novel TMA lyase inhibitors designed to reduce serum TMAO.
- Assessment of clinical endpoints in patients treated with TMA lyase inhibitors.
Main Results:
- TMA lyase inhibitors significantly decrease serum TMAO levels.
- These inhibitors improve cardiovascular risk factors, including blood pressure and glycemic control.
- Observed benefits include reduced platelet aggregation, fewer major adverse cardiac events, and slower renal dysfunction progression.
Conclusions:
- TMA lyase inhibitors offer a promising therapeutic strategy for TMAO-related conditions.
- Targeting TMA production may mitigate risks associated with cardiovascular disease, inflammation, and potentially cancer.
- Further research is essential to fully elucidate the therapeutic potential of TMAO-lowering agents.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:14Myocarditis III: Medical Management
153
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
153
01:16Antianginal Drugs: Nitrates and β-Blockers
1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
590
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
590
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
849
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
849